Celcuity Inc - Understand $celc stock

$CELC Market Cap: $554.7 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$82.59M

TTM

Current Assets

$291.9M

Q2 2024

Current Liabilities

$19.53M

Q2 2024

Current Ratio

1494.9%

Q2 2024

Total Assets

$292.5M

Q2 2024

Total Liabilities

$115.9M

Q2 2024

Book Value

$176.7M

Q2 2024

Cash

$30.46M

Q2 2024

P/E

-6.717

Sep 17, 2024 EST

Free Cash Flow

-$66.66M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	$5.636M	$4.102M	$2.598M	$1.870M	$1.540M	$1.610M	$970.0K	$260.0K	$250.0K
YoY Change	37.42%	57.88%	38.93%	21.43%	-4.35%	65.98%	273.08%	4.0%
% of Gross Profit
Research & Development	$60.59M	$35.29M	$25.76M	$7.684M	$6.269M	$6.326M	$4.980M	$3.065M	$2.010M
YoY Change	71.71%	37.0%	235.24%	22.56%	-0.9%	27.02%	62.51%	52.48%
% of Gross Profit
Depreciation & Amortization	$142.8K	$210.9K	$303.2K	$385.6K	$339.0K	$223.0K	$104.7K	$73.06K	$60.00K
YoY Change	-32.31%	-30.45%	-21.36%	13.74%	51.99%	113.02%	43.31%	21.77%
% of Gross Profit
Operating Expenses	$66.23M	$39.39M	$28.36M	$9.556M	$7.805M	$7.933M	$5.953M	$3.328M	$2.260M
YoY Change	68.14%	38.92%	196.73%	22.43%	-1.6%	33.25%	78.85%	47.28%
Operating Profit	-$66.23M	-$39.39M	-$28.36M	-$9.556M	-$7.805M	-$7.933M	-$5.953M	-$3.328M
YoY Change	68.14%	38.92%	196.73%	22.43%	-1.6%	33.25%	78.85%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Interest Expense	$5.326M	$2.106M	-$1.249M	$120.00	$159.00	$111.00	$451.7K	$0.00	$0.00
YoY Change	152.9%	-268.61%	-1041008.33%	-24.53%	43.24%	-99.98%
% of Operating Profit
Other Income/Expense, Net	$2.451M	-$978.9K	-$1.249M	$81.99K	$445.9K	$451.7K	-$298.8K	$18.02K
YoY Change	-350.39%	-21.64%	-1623.8%	-81.61%	-1.28%	-251.19%	-1758.26%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Pretax Income	-$63.78M	-$40.37M	-$29.61M	-$9.474M	-$7.359M	-$7.481M	-$6.252M	-$3.310M	-$2.260M
YoY Change	57.99%	36.36%	212.48%	28.74%	-1.62%	19.66%	88.85%	46.48%
Income Tax					$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$63.78M	-$40.37M	-$29.61M	-$9.474M	-$7.359M	-$7.481M	-$6.252M	-$3.310M	-$2.260M
YoY Change	57.99%	36.36%	212.48%	28.74%	-1.62%	19.66%	88.85%	46.48%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.69	-$2.64	-$2.21
Diluted Earnings Per Share	-$2.69	-$2.62	-$2.212M	-$922.1K	-$719.5K	-$739.1K	-$837.8K	-$353.3K	-$241.2K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Short-Term Investments	$180.6M	$168.6M	$84.29M	$11.64M	$18.74M	$24.90M	$24.20M	$5.860M	$5.070M
YoY Change	7.12%	100.02%	624.11%	-37.89%	-24.74%	2.89%	312.97%	15.58%
Cash & Equivalents	$30.66M	$24.57M	$84.29M	$11.64M	$18.74M	$15.94M	$2.640M	$5.860M	$5.070M
Short-Term Investments	$149.9M	$144.0M			$0.00	$8.950M	$21.56M
Other Short-Term Assets	$9.202M	$6.399M	$766.8K	$340.0K	$320.0K	$320.0K	$290.0K	$60.00K	$60.00K
YoY Change	43.8%	734.52%	125.54%	6.25%	0.0%	10.34%	383.33%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$190.6M	$175.2M	$85.35M	$12.17M	$19.25M	$25.22M	$24.48M	$5.910M	$5.120M
YoY Change	8.79%	105.26%	601.33%	-36.78%	-23.67%	3.02%	314.21%	15.43%
Property, Plant & Equipment	$628.8K	$506.6K	$554.4K	$790.0K	$1.030M	$810.0K	$280.0K	$140.0K	$180.0K
YoY Change	24.13%	-8.62%	-29.83%	-23.3%	27.16%	189.29%	100.0%	-22.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments						$0.00	$7.210M
YoY Change						-100.0%
Other Assets
YoY Change
Total Long-Term Assets	$628.8K	$506.6K	$554.3K	$790.0K	$1.030M	$810.0K	$7.490M	$150.0K	$180.0K
YoY Change	24.13%	-8.62%	-29.83%	-23.3%	27.16%	-89.19%	4893.33%	-16.67%
Total Assets	$191.2M	$175.7M	$85.91M	$12.96M	$20.28M	$26.03M	$31.97M	$6.060M	$5.300M
YoY Change
Accounts Payable	$5.077M	$2.627M	$1.507M	$220.0K	$140.0K	$120.0K	$70.00K	$330.0K	$260.0K
YoY Change	93.24%	74.31%	585.05%	57.14%	16.67%	71.43%	-78.79%	26.92%
Accrued Expenses	$2.647M	$2.005M	$854.0K	$960.0K	$760.0K	$470.0K	$510.0K	$110.0K	$20.00K
YoY Change	32.0%	134.84%	-11.05%	26.32%	61.7%	-7.84%	363.64%	450.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$2.450K	$5.850K	$10.00K	$10.00K	$10.00K
YoY Change		-58.12%	-41.5%	0.0%	0.0%
Total Short-Term Liabilities	$14.19M	$6.882M	$2.506M	$1.190M	$910.0K	$660.0K	$580.0K	$450.0K	$280.0K
YoY Change	106.19%	174.64%	110.56%	30.77%	37.88%	13.79%	28.89%	60.71%
Long-Term Debt	$37.04M	$34.98M	$14.63M	$10.00K	$10.00K	$20.00K	$0.00	$0.00	$0.00
YoY Change	5.87%	139.15%	146183.7%	0.0%	-50.0%
Other Long-Term Liabilities	$225.9K	$61.00K	$61.77K	$60.00K	$60.00K
YoY Change	270.36%	-1.25%	2.95%	0.0%
Total Long-Term Liabilities	$37.26M	$35.04M	$14.69M	$70.00K	$70.00K	$20.00K	$0.00	$0.00	$0.00
YoY Change	6.33%	138.56%	20885.91%	0.0%	250.0%
Total Liabilities	$51.45M	$41.93M	$17.20M	$1.250M	$980.0K	$680.0K	$580.0K	$450.0K	$280.0K
YoY Change	22.72%	143.81%	1275.67%	27.55%	44.12%	17.24%	28.89%	60.71%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	23.68M shares	15.42M shares	13.38M shares
Diluted Shares Outstanding	23.68M shares	15.42M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $554.71 Million

About Celcuity Inc

Celcuity, Inc. is cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 55 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.

Industry: Services-Medical Laboratories Peers: AVITA Medical Inc PARDES BIOSCIENCES, INC. Icosavax, Inc. IPI Legacy Liquidation Co Matinas BioPharma Holdings Inc Ovid Therapeutics Inc Precision BioSciences Inc Tenaya Therapeutics Inc Werewolf Therapeutics Inc